Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panalife Sinus is an oral combination pharmaceutical product developed by LIFEPharma for the symptomatic relief of sinus pain and nasal congestion. It contains paracetamol (acetaminophen), a non-aspirin analgesic and antipyretic, and pseudoephedrine hydrochloride, a sympathomimetic decongestant. Paracetamol works primarily by inhibiting prostaglandin synthesis in the central nervous system, which elevates the pain threshold and reduces fever. Pseudoephedrine hydrochloride acts as a sympathomimetic agent that targets alpha-adrenergic receptors in the respiratory tract mucosa, leading to vasoconstriction that reduces tissue swelling and nasal congestion. The medication is approved for the treatment of sinus headache, sinus pressure, and nasal blockage associated with the common cold, sinusitis, or allergic rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + pseudoephedrine hydrochloride.